News
![EQS-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
![EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
![Lonza Increases Straight Bond by CHF 150 Million](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lonza Increases Straight Bond by CHF 150 Million
Lonza Increases Straight Bond by CHF 150 Million
![EQS-News: Abivax reports 2022 financial results and operations update](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-News: Abivax reports 2022 financial results and operations update
EQS-News: Abivax reports 2022 financial results and operations update
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
![Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
![Convatec Group PLC: Scrip Dividend - Calculation Price](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Convatec Group PLC: Scrip Dividend - Calculation Price
Convatec Group PLC: Scrip Dividend - Calculation Price
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
![Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
![EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
![EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
![Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
![Relief Therapeutics Announces Executive Leadership Team Change](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Relief Therapeutics Announces Executive Leadership Team Change
Relief Therapeutics Announces Executive Leadership Team Change
![EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
![Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
![Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
![Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
![Lonza Launches Share Buyback Program of up to CHF 2 Billion](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
![Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
![Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
![Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc